Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

In 2023 – the first year that Arexvy and Abrysvo were approved – the ACIP's recommendation was that they could be used in all adults over the age of 60 if deemed appropriate by their doctor ...

As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they ...

Stocks ended in the red for the holiday-shortened week, as developments over tariffs and tensions between U.S. President Donald Trump and Federal Reserve chair Jerome Powell continued to dominate ...

Respiratory syncytial virus (RSV) vaccines Arexvy, from GSK, and Abrysvo, from Pfizer, received affirmative ACIP votes for use in adults age 50 to 59 who are at increased risk of RSV disease ...

For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...